OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
TIDT56

Trident Lifeline Ltd

PharmaceuticalsVerified

Trident Lifeline's capital structure shows a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.69, suggesting it can cover its short-term obligations with its current assets. However, the operating cash flow is negative at -102.4 million INR, which may signal short-term liquidity challenges. In terms of profitability, the company's return on equity (ROE) is 18.23%, and its return on assets (ROA) is 7.53%. These figures are above the industry median for ROE and ROA, indicating that Trident Lifeline is generating strong returns relative to its equity and asset base. The company's revenue is distributed across several geographic segments, with a notable presence in India and other international markets. However, the financial data does not provide specific revenue concentration figures for each segment, making it difficult to assess the level of geographic diversification. Trident Lifeline's growth trajectory is not explicitly detailed in the provided data, but the company's operating income and net income figures suggest a stable performance. The outlook for the current fiscal year is not provided, but the company's free cash flow of 48.9 million INR indicates some capacity for reinvestment or shareholder returns. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet long-term obligations. The dilution risk is low, and there are no immediate signs of significant equity dilution. Recent events and filings are not detailed in the provided data, so there is no specific information on recent corporate actions or strategic developments. The company's financial statements and disclosures would need to be reviewed for more detailed insights into recent business activities.

30-day price · TIDT-12.75 (-4.8%)
Low$240.00High$306.00Close$253.50As of15 May, 00:00 UTC
Profile
CompanyTrident Lifeline Ltd
TickerTIDT.BO
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Trident Lifeline Limited (TLL) is an India-based medication provider that produces and sells finished doses across multiple geographies, including India, Ghana, Kenya, Peru, Cameroon, Venezuela, and the Rest of the World.

Classification. Trident Lifeline is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector and the Pharmaceuticals industry, with a confidence level of 0.92.

Trident Lifeline's capital structure shows a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.69, suggesting it can cover its short-term obligations with its current assets. However, the operating cash flow is negative at -102.4 million INR, which may signal short-term liquidity challenges. In terms of profitability, the company's return on equity (ROE) is 18.23%, and its return on assets (ROA) is 7.53%. These figures are above the industry median for ROE and ROA, indicating that Trident Lifeline is generating strong returns relative to its equity and asset base. The company's revenue is distributed across several geographic segments, with a notable presence in India and other international markets. However, the financial data does not provide specific revenue concentration figures for each segment, making it difficult to assess the level of geographic diversification. Trident Lifeline's growth trajectory is not explicitly detailed in the provided data, but the company's operating income and net income figures suggest a stable performance. The outlook for the current fiscal year is not provided, but the company's free cash flow of 48.9 million INR indicates some capacity for reinvestment or shareholder returns. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet long-term obligations. The dilution risk is low, and there are no immediate signs of significant equity dilution. Recent events and filings are not detailed in the provided data, so there is no specific information on recent corporate actions or strategic developments. The company's financial statements and disclosures would need to be reviewed for more detailed insights into recent business activities.
Key takeaways
  • Trident Lifeline has a strong return on equity (18.23%) and return on assets (7.53%), indicating efficient use of capital and assets.
  • The company's debt-to-equity ratio of 0.84 suggests a balanced capital structure with moderate leverage.
  • The current ratio of 1.69 indicates the company can cover its short-term liabilities with its current assets.
  • The negative operating cash flow of -102.4 million INR may signal short-term liquidity challenges.
  • The company's liquidity risk is assessed as medium, and its dilution risk is low.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$869.6M
Gross profit$414.1M
Operating income$93.7M
Net income$117.5M
R&D
SG&A
D&A
SBC
Operating cash flow-$102.4M
CapEx-$111.0M
Free cash flow$48.9M
Total assets$1.56B
Total liabilities$915.5M
Total equity$644.6M
Cash & equivalents
Long-term debt$540.3M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$644.6M
Net cash-$540.3M
Current ratio1.7
Debt/Equity0.8
ROA7.5%
ROE18.2%
Cash conversion-87.0%
CapEx/Revenue-12.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricTIDTActivity
Op margin10.8%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin13.5%14.7% medp25 11.7% · p75 28.1%below median
Gross margin47.6%19.7% medp25 19.7% · p75 39.8%top quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-12.8%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity84.0%71.3% medp25 19.0% · p75 91.7%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 14:01 UTC#66e966e2
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 14:34 UTCJob: fee3bfc7